USANA Health Sciences Inc. reported an insider sale by Chief Legal Officer Joshua Foukas that reduced his direct stake in the company to zero. According to a Form 4 filing with the Securities and Exchange Commission, Foukas sold 4,461 shares of USANA common stock on February 20, 2026, at a price of $21.345 per share. The transaction generated proceeds of approximately $95,220.
At the time of the disclosure, USANA's shares were trading at $21.82, and the stock had declined about 32% over the previous six months.
Separately, the filing shows that on February 19, 2026, Foukas was awarded 36,662 restricted stock units (RSUs). Those RSUs are scheduled to vest in four equal installments, with 25% vesting on each February 19th following the grant date.
Company guidance and operational outlook
USANA has issued updated near-term revenue guidance. For fiscal year 2025, the company now anticipates net sales of approximately $925 million, a modest increase from its previous guidance of $920 million. Looking to 2026, USANA provided an initial sales forecast in a range between $925 million and $1 billion.
The company expects its core nutritional business to experience a contraction in sales next year. Management projects core nutrition revenue in 2026 to fall between $720 million and $765 million, compared with roughly $777 million in 2025.
Partnership update
In addition to its financial outlook, USANA extended its relationship with the Jamaica Bobsleigh and Skeleton Federation through 2032. Under the agreement, USANA will continue supplying nutritional products to the athletes and will have its logo displayed on the team’s equipment and racing apparel.
Summary of facts
- Joshua Foukas sold 4,461 shares on February 20, 2026, at $21.345 per share for about $95,220.
- Following the sale, Foukas directly holds zero shares of USANA.
- Foukas received 36,662 RSUs on February 19, 2026, vesting 25% on each subsequent February 19th.
- USANA updated fiscal 2025 net sales guidance to around $925 million and provided an initial 2026 sales range of $925 million to $1 billion.
- Core nutrition sales are forecast to decline to $720 million–$765 million in 2026 from about $777 million in 2025.
- USANA extended its sponsorship with the Jamaica Bobsleigh and Skeleton Federation through 2032.
Key points
- Insider activity: A senior lawyer at USANA sold shares and now holds no direct stock, while receiving an RSU grant that vests over four years.
- Financial guidance: The company raised its near-term sales estimate for 2025 and issued a preliminary revenue range for 2026 that includes a potential top end of $1 billion.
- Brand and partnerships: USANA renewed its sports partnership through 2032, maintaining product supply and branding on team equipment.
Risks and uncertainties
- Revenue trajectory: USANA projects a decline in sales for its core nutritional business in 2026, which could affect overall company performance if realized.
- Insider disposition: The sale by a senior executive reduced his direct holdings to zero; the market may interpret such moves in different ways, but no further information on intent was provided.
- Forecast range: The 2026 sales estimate covers a broad range ($925 million to $1 billion), reflecting uncertainty in near-term top-line outcomes.